SLC5A2 and hydrops fetalis: Several landmark randomized‐controlled trials (RCT)s have demonstrated the efficacy of sodium‐glucose co‐transport 2 (SGLT2) inhibitors in reducing all‐cause mortality, cardiovascular (CV) mortality and rates of heart failure (HF) hospitalizations in patients with HF.1, 2, 3, 4, 5